{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:05:59Z","timestamp":1695963959757},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,4,11]],"date-time":"2006-04-11T00:00:00Z","timestamp":1144713600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Daptomycin is a novel cyclic lipopeptide whose bactericidal activity is not affected by current antibiotic resistance mechanisms displayed by <jats:italic>S. aureus<\/jats:italic> clinical isolates. This study reports the therapeutic activity of high-dose daptomycin compared to standard regimens of oxacillin and vancomycin in a difficult-to-treat, rat tissue cage model of experimental therapy of chronic <jats:italic>S. aureus<\/jats:italic> foreign body infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The methicillin-susceptible <jats:italic>S. aureus<\/jats:italic> (MSSA) strain I20 is a clinical isolate from catheter-related sepsis. MICs, MBCs, and time-kill curves of each antibiotic were evaluated as recommended by NCCLS, including supplementation with physiological levels (50 mg\/L) of Ca<jats:sup>2+<\/jats:sup> for daptomycin. Two weeks after local infection of subcutaneously implanted tissue cages with MSSA I20, each animal received (i.p.) twice-daily doses of daptomycin, oxacillin, or vancomycin for 7 days, or was left untreated. The reductions of CFU counts in each treatment group were analysed by ANOVA and Newman-Keuls multiple comparisons procedures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The MICs and MBCs of daptomycin, oxacillin, or vancomycin for MSSA strain I20 were 0.5 and 1, 0.5 and 1, or 1 and 2 mg\/L, respectively. In vitro elimination of strain I20 was more rapid with 8 mg\/L of daptomycin compared to oxacillin or vancomycin. Twice-daily administered daptomycin (30 mg\/kg), oxacillin (200 mg\/kg), or vancomycin (50 mg\/kg vancomycin) yielded bactericidal antibiotic levels in infected cage fluids throughout therapy. Before therapy, mean (\u00b1 SEM) viable counts of strain I20 were 6.68 \u00b1 0.10 log<jats:sub>10<\/jats:sub> CFU\/mL of cage fluid (n = 74). After 7 days of therapy, the mean (\u00b1 SEM) reduction in viable counts of MSSA I20 was 2.62 (\u00b1 0.30) log<jats:sub>10<\/jats:sub> CFU\/mL in cages (n = 18) of daptomycin-treated rats, exceeding by &gt;2-fold (<jats:italic>P<\/jats:italic> &lt; 0.01) the viable count reductions of 0.92 (\u00b1 0.23; n = 19) and 0.96 (\u00b1 0.24; n = 18) log<jats:sub>10<\/jats:sub> CFU\/mL in cages of oxacillin-treated and vancomycin-treated rats, respectively. Viable counts in cage fluids of untreated animals increased by 0.48 (\u00b1 0.24; n = 19) log<jats:sub>10<\/jats:sub> CFU\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The improved efficacy of the twice-daily regimen of daptomycin (30 mg\/kg) compared to oxacillin (200 mg\/kg) or vancomycin (50 mg\/kg) may result from optimisation of its pharmacokinetic and bactericidal properties in infected cage fluids.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-6-74","type":"journal-article","created":{"date-parts":[[2006,4,20]],"date-time":"2006-04-20T14:36:57Z","timestamp":1145543817000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection"],"prefix":"10.1186","volume":"6","author":[{"given":"Heinz J","family":"Schaad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Bento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Vaudaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,4,11]]},"reference":[{"key":"338_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/9781555818067","volume-title":"Infections associated with indwelling medical devices","author":"FA Waldvogel","year":"2000","unstructured":"Waldvogel FA, Bisno AL: Infections associated with indwelling medical devices. Edited by: Waldvogel FA and Bisno AL. 2000, Washington, DC, American Society for Microbiology, 1-436. 3rd","edition":"3rd"},{"key":"338_CR2","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1086\/320184","volume":"32","author":"DJ Diekema","year":"2001","unstructured":"Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M, SENTRY PG: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001, 32: S114-S132. 10.1086\/320184.","journal-title":"Clin Infect Dis"},{"key":"338_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1172\/JCI18535","volume":"111","author":"FD Lowy","year":"2003","unstructured":"Lowy FD: Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003, 111: 1265-1273. 10.1172\/JCI200318535.","journal-title":"J Clin Invest"},{"key":"338_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3201\/eid0702.010204","volume":"7","author":"HF Chambers","year":"2001","unstructured":"Chambers HF: The changing epidemiology of Staphylococcus aureus?. Emerg Infect Dis. 2001, 7: 178-182.","journal-title":"Emerg Infect Dis"},{"key":"338_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","volume":"1","author":"K Hiramatsu","year":"2001","unstructured":"Hiramatsu K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001, 1: 147-155. 10.1016\/S1473-3099(01)00091-3.","journal-title":"Lancet Infect Dis"},{"key":"338_CR6","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","volume":"47","author":"C Liu","year":"2003","unstructured":"Liu C, Chambers HF: Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003, 47: 3040-3045. 10.1128\/AAC.47.10.3040-3045.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJMoa025025","volume":"348","author":"S Chang","year":"2003","unstructured":"Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003, 348: 1342-1347. 10.1056\/NEJMoa025025.","journal-title":"N Engl J Med"},{"key":"338_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1086\/383472","volume":"38","author":"CF Carpenter","year":"2004","unstructured":"Carpenter CF, Chambers HF: Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004, 38: 994-1000. 10.1086\/383472.","journal-title":"Clin Infect Dis"},{"key":"338_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jac\/dkh546","volume":"55","author":"JN Steenbergen","year":"2005","unstructured":"Steenbergen JN, Alder J, Thorne GM, Tally FP: Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005, 55: 283-288. 10.1093\/jac\/dkh546.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(05)70051-7","volume":"5","author":"RE Hancock","year":"2005","unstructured":"Hancock RE: Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis. 2005, 5: 209-218. 10.1016\/S1473-3099(05)70051-7.","journal-title":"Lancet Infect Dis"},{"key":"338_CR11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ajhp\/62.11.1145","volume":"62","author":"CA Schriever","year":"2005","unstructured":"Schriever CA, Fernandez C, Rodvold KA, Danziger LH: Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm. 2005, 62: 1145-1158.","journal-title":"Am J Health Syst Pharm"},{"key":"338_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/jac\/46.4.523","volume":"46","author":"FP Tally","year":"2000","unstructured":"Tally FP, DeBruin MF: Development of daptomycin for Gram-positive infections. J Antimicrob Chemother. 2000, 46: 523-526. 10.1093\/jac\/46.4.523.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004, 38: 1673-1681. 10.1086\/420818.","journal-title":"Clin Infect Dis"},{"key":"338_CR14","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","volume":"47","author":"JA Silverman","year":"2003","unstructured":"Silverman JA, Perlmutter NG, Shapiro HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003, 47: 2538-2544. 10.1128\/AAC.47.8.2538-2544.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jac\/48.2.219","volume":"48","author":"A King","year":"2001","unstructured":"King A, Phillips I: The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother. 2001, 48: 219-223. 10.1093\/jac\/48.2.219.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR16","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1128\/AAC.44.12.3447-3450.2000","volume":"44","author":"DR Snydman","year":"2000","unstructured":"Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM: Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother. 2000, 44: 3447-3450. 10.1128\/AAC.44.12.3447-3450.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","volume":"45","author":"AL Barry","year":"2001","unstructured":"Barry AL, Fuchs PC, Brown SD: In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001, 45: 1919-1922. 10.1128\/AAC.45.6.1919-1922.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/jac\/48.4.563","volume":"48","author":"R Wise","year":"2001","unstructured":"Wise R, Andrews JM, Ashby JP: Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother. 2001, 48: 563-567. 10.1093\/jac\/48.4.563.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR19","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1128\/AAC.35.9.1710","volume":"35","author":"H Hanberger","year":"1991","unstructured":"Hanberger H, Nilsson LE, Maller R, Isaksson B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991, 35: 1710-1716.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/jac\/49.3.467","volume":"49","author":"PC Fuchs","year":"2002","unstructured":"Fuchs PC, Barry AL, Brown SD: In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother. 2002, 49: 467-470. 10.1093\/jac\/49.3.467.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","volume":"48","author":"N Safdar","year":"2004","unstructured":"Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004, 48: 63-68. 10.1128\/AAC.48.1.63-68.2004.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","volume":"45","author":"A Louie","year":"2001","unstructured":"Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2001, 45: 845-851. 10.1128\/AAC.45.3.845-851.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jac\/dkg337","volume":"52","author":"PK Dandekar","year":"2003","unstructured":"Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP: Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother. 2003, 52: 405-411. 10.1093\/jac\/dkg337.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR24","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1128\/AAC.33.9.1522","volume":"33","author":"S Kennedy","year":"1989","unstructured":"Kennedy S, Chambers HF: Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother. 1989, 33: 1522-1525.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR25","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1128\/AAC.34.12.2348","volume":"34","author":"L Cantoni","year":"1990","unstructured":"Cantoni L, Glauser MP, Bille J: Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother. 1990, 34: 2348-2353.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR26","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1128\/AAC.34.11.2081","volume":"34","author":"GW Kaatz","year":"1990","unstructured":"Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ: Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990, 34: 2081-2085.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/AAC.38.3.487","volume":"38","author":"GP Voorn","year":"1994","unstructured":"Voorn GP, Kuyvenhoven J, Goessens WH, Schmal-Bauer WC, Broeders PH, Thompson J, Michel MF: Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother. 1994, 38: 487-493.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR28","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1086\/430352","volume":"191","author":"JA Silverman","year":"2005","unstructured":"Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005, 191: 2149-2152. 10.1086\/430352.","journal-title":"J Infect Dis"},{"key":"338_CR29","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","volume":"47","author":"BH Dvorchik","year":"2003","unstructured":"Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003, 47: 1318-1323. 10.1128\/AAC.47.4.1318-1323.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR30","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","volume":"44","author":"FBJ Oleson","year":"2000","unstructured":"Oleson FBJ, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000, 44: 2948-2953. 10.1128\/AAC.44.11.2948-2953.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1517\/13543784.8.8.1223","volume":"8","author":"FP Tally","year":"2001","unstructured":"Tally FP, Zeckel ML, Wasilewski M, Carini C, Berman CL, Drusano GL, Oleson FBJ: Daptomycin: a novel agent for Gram-positive infections. Experimental Opinion on Investigational Drugs. 2001, 8: 1223-1238. 10.1517\/13543784.8.8.1223.","journal-title":"Experimental Opinion on Investigational Drugs"},{"key":"338_CR32","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1128\/AAC.34.12.2312","volume":"34","author":"JC Lucet","year":"1990","unstructured":"Lucet JC, Herrmann M, Rohner P, Auckenthaler R, Waldvogel FA, Lew DP: Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990, 34: 2312-2317.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/33.6.1191","volume":"33","author":"HJ Schaad","year":"1994","unstructured":"Schaad HJ, Chuard C, Vaudaux P, Rohner P, Waldvogel FA, Lew DP: Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin- susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother. 1994, 33: 1191-1200.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR34","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1128\/AAC.38.8.1703","volume":"38","author":"HJ Schaad","year":"1994","unstructured":"Schaad HJ, Chuard C, Vaudaux P, Waldvogel FA, Lew DP: Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994, 38: 1703-1710.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR35","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1128\/AAC.39.8.1655","volume":"39","author":"A Cagni","year":"1995","unstructured":"Cagni A, Chuard C, Vaudaux P, Schrenzel J, Lew DP: Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicilin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1995, 39: 1655-1660.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR36","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1128\/AAC.46.5.1503-1509.2002","volume":"46","author":"P Vaudaux","year":"2002","unstructured":"Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew DP: Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002, 46: 1503-1509. 10.1128\/AAC.46.5.1503-1509.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/jac\/dkg277","volume":"52","author":"P Vaudaux","year":"2003","unstructured":"Vaudaux P, Francois P, Bisognano C, Li D, Lew DP, Schrenzel J: Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother. 2003, 52: 89-95. 10.1093\/jac\/dkg277.","journal-title":"J Antimicrob Chemother"},{"key":"338_CR38","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1128\/AAC.49.9.3789-3793.2005","volume":"49","author":"P Vaudaux","year":"2005","unstructured":"Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP: Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005, 49: 3789-3793. 10.1128\/AAC.49.9.3789-3793.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR39","first-page":"Abstract B-274","volume-title":"42nd Intersci Conf Antimicrob Agents Chemother , San Diego, CA","author":"P Vaudaux","year":"2002","unstructured":"Vaudaux P, Schaad H, Francois P, Bisognano C, Chuard C, Schrenzel J, Lew D: Efficacy of a high dose regimen of daptomycin compared to oxacillin and vancomycin in the therapy of experimental foreign body infection due to methicillin-susceptible Staphylococcus aureus. 42nd Intersci Conf Antimicrob Agents Chemother , San Diego, CA. 2002, Abstract B-274-"},{"key":"338_CR40","first-page":"Abstract K-426a","volume-title":"45th Intersci Conf Antimicrob Agents Chemother , Washington, DC","author":"E Abrutyn","year":"2005","unstructured":"Fowler, V., Cosgrove, S., Abrutyn E, Boucher, H., Chambers, H., Corey, G., Demeyer, I., Filler, S., Levine, D., Link, A., Rupp, M., Karchmer, A.: Daptomycin vs. standard therapy for Staphylococcus aureus bacteremia and infective endocarditis. 45th Intersci Conf Antimicrob Agents Chemother , Washington, DC. 2005, Abstract K-426a-"},{"key":"338_CR41","first-page":"Abstract LB-2","volume-title":"45th Intersci Conf Antimicrob Agents Chemother , Washington DC","author":"Benvenuto","year":"2005","unstructured":"Benvenuto, M., Benziger, D., Yankelev, S., Summers, E., Vigliani, G.: Safety and pharmacokinetics of daptomycin at doses up to 12 mg\/kg daily. 45th Intersci Conf Antimicrob Agents Chemother , Washington DC. 2005, Abstract LB-2-"},{"key":"338_CR42","first-page":"Abstract B-2008","volume-title":"45th Intersci Conf Antimicrob Agents Chemother , Washington, DC","author":"MS Rouse","year":"2005","unstructured":"Rouse MS, Piper KE, Jacobson, M.J., Steckelberg JM, Patel R: Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. 45th Intersci Conf Antimicrob Agents Chemother , Washington, DC. 2005, Abstract B-2008-"},{"key":"338_CR43","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/infdis\/163.6.1369","volume":"163","author":"C Chuard","year":"1991","unstructured":"Chuard C, Lucet JC, Rohner P, Herrmann M, Auckenthaler R, Waldvogel FA, Lew DP: Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis. 1991, 163: 1369-1373.","journal-title":"J Infect Dis"},{"key":"338_CR44","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th. ed. Approved Standard. CLSI document M7-A6, Vol. 23","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2003","unstructured":"Clinical and Laboratory Standards Institute (CLSI): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th. ed. Approved Standard. CLSI document M7-A6, Vol. 23. Edited by: CLSI . 2003, Wayne, Pa., 6th. ed. Approved Standard:"},{"key":"338_CR45","first-page":"1","volume-title":"Fundamentals of biostatistics","author":"B Rosner","year":"1990","unstructured":"Rosner B: Fundamentals of biostatistics. 1990, Belmont, CA, Duxbury Press, 1-655. 3rd","edition":"3rd"},{"key":"338_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1128\/AAC.34.1.21","volume":"34","author":"N Bouchenaki","year":"1990","unstructured":"Bouchenaki N, Vaudaux P, Huggler E, Waldvogel FA, Lew DP: Successful single-dose prophylaxis of Staphylococcus aureus foreign body infection in guinea pigs by fleroxacin. Antimicrob Agents Chemother. 1990, 34: 21-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"338_CR47","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1128\/AAC.47.5.1714-1718.2003","volume":"47","author":"G Sakoulas","year":"2003","unstructured":"Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT: Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003, 47: 1714-1718. 10.1128\/AAC.47.5.1714-1718.2003.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-6-74.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-6-74\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-6-74","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-6-74.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:34:31Z","timestamp":1630449271000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-6-74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,11]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-6-74","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,11]]},"assertion":[{"value":"17 February 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"74"}}